Rohit Antal Rohit Buys 3,315 Shares of PROCEPT BioreRobotics Amid 50% Stock Decline: Insider Confidence Signals Possible Upside Trajectory

Insider Buying Signals Amid a Volatile Year

On June 9 2026, director Desai Antal Rohit added 3,315 restricted‑stock units and 5,853 stock‑option rights to his portfolio, bringing his holdings to 38,467 shares of PROCEPT BioreRobotics’ common stock. The transaction came at a price of $29.09, barely above the intraday close of $28.78, and is a classic vesting‑triggered buy. In a year when the company’s stock has lost more than 50 % of its value, Rohit’s continued accumulation signals confidence that the management team and the underlying technology—autonomous tissue removal for benign prostatic hyperplasia—are on a credible upside trajectory.

What This Means for Investors

Rohit’s buying pattern over the last 90 days has been aggressive and consistent. From early March through early June, he has purchased roughly 1.5 million shares at average prices ranging from $23.33 to $25.44, adding more than 30 % to his stake in the company. Unlike the off‑market sales seen from CFO Kevin Waters and CLO Nouri Alaleh in early June—each selling less than 1,000 shares—Rohit’s actions illustrate a belief that the current valuation is a “buy low” opportunity. For retail and institutional investors, this insider buying can be read as a bullish endorsement, especially when paired with the 554 % social‑media buzz that suggests market participants are paying close attention to the company’s upcoming earnings and regulatory filings.

A Profile of Rohit’s Trading Style

Rohit’s transaction history shows a clear preference for large, cumulative purchases over short‑term speculation. In June 2025 alone, he sold a total of 19,300 shares, but his March 2026 buying spree more than offset those outflows, netting a net increase of 24,000 shares in a single month. His trades are usually executed at market‑close prices, indicating a long‑term horizon rather than day‑trading. The absence of any large sell‑offs in 2026 suggests he remains patient for a breakout after the company’s 2026 fiscal year ends.

Industry Context and Forward Outlook

PROCEPT BioreRobotics operates in a highly competitive surgical‑equipment niche, but its autonomous‑tissue‑removal platform has attracted significant investor interest, as evidenced by the recent rule 144 sale disclosures. With a market cap of $1.58 billion and a trailing P/E of –14.61, the stock is undervalued relative to peers. If the company can deliver on its product‑launch timelines and secure regulatory approvals, the insider activity may presage a rally. Conversely, continued earnings volatility could erode the confidence that Rohit and other insiders appear to have.

Bottom Line for Stakeholders

Rohit Antal Rohit’s fresh buy, combined with his cumulative 3‑month buying momentum, signals a long‑term belief in PROCEPT’s technology and market potential. For investors, it is a cue to monitor the company’s upcoming regulatory filings, product milestones, and any changes in management’s equity plans. Should the company deliver on its ambitious roadmap, the stock could move sharply higher—offering a compelling case for a disciplined, long‑term position in this high‑growth biotech platform.